Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. www.sciencedirect.com/science/article/pii/S1871402121002046.
This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: www.nejm.org/doi/full/10.1056/NEJMoa2104983.
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: pubmed.ncbi.nlm.nih.gov/33444297/
Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: pubmed.ncbi.nlm.nih.gov/33507892/
Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: pubmed.ncbi.nlm.nih.gov/34414880/
Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: pubmed.ncbi.nlm.nih.gov/33576785/
Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: pubmed.ncbi.nlm.nih.gov/34269740/
Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34215453/
Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): pubmed.ncbi.nlm.nih.gov/33643776/
Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: pubmed.ncbi.nlm.nih.gov/34347278/
Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/
Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: pubmed.ncbi.nlm.nih.gov/33657648/
Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: pubmed.ncbi.nlm.nih.gov/33919151/
Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: pubmed.ncbi.nlm.nih.gov/34128049/
Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: pubmed.ncbi.nlm.nih.gov/34474708/
Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: pubmed.ncbi.nlm.nih.gov/33752263/
A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: pubmed.ncbi.nlm.nih.gov/34423106/
Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: pubmed.ncbi.nlm.nih.gov/33838206/
Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: pubmed.ncbi.nlm.nih.gov/34517079/
Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: pubmed.ncbi.nlm.nih.gov/34254291/
Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: pubmed.ncbi.nlm.nih.gov/34487581/
Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: pubmed.ncbi.nlm.nih.gov/33987882/
Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34138513/
Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: pubmed.ncbi.nlm.nih.gov/34402235/
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: pubmed.ncbi.nlm.nih.gov/34446426/
Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: pubmed.ncbi.nlm.nih.gov/34365148/.
Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: pubmed.ncbi.nlm.nih.gov/34452064/.
A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33917902/
Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): pubmed.ncbi.nlm.nih.gov/34256983/
Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34247246/.
Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34132839/
59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34117206/
Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: pubmed.ncbi.nlm.nih.gov/34033927/
Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/
Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: pubmed.ncbi.nlm.nih.gov/34453510/
Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: pubmed.ncbi.nlm.nih.gov/34272095/
Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: pubmed.ncbi.nlm.nih.gov/34492394/
Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34369471/
A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34272622/
Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: pubmed.ncbi.nlm.nih.gov/34139321/.
Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: pubmed.ncbi.nlm.nih.gov/34293683/.
A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: pubmed.ncbi.nlm.nih.gov/34449715/
Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: pubmed.ncbi.nlm.nih.gov/34139631/.
Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/33864750/
Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/33914590/
Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: pubmed.ncbi.nlm.nih.gov/34293217/
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: pubmed.ncbi.nlm.nih.gov/34446426/
Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34174723/
Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: pubmed.ncbi.nlm.nih.gov/33952445/
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: pubmed.ncbi.nlm.nih.gov/34108714/
#4 Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34341358/
celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: pubmed.ncbi.nlm.nih.gov/34261633/.
central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: pubmed.ncbi.nlm.nih.gov/34478433/
Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: pubmed.ncbi.nlm.nih.gov/34402235/
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: pubmed.ncbi.nlm.nih.gov/34186376/
A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34137813/
Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: pubmed.ncbi.nlm.nih.gov/34191218/
Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/
Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261635/
Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34132839/.
Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34144250/
Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34011137/.
Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: pubmed.ncbi.nlm.nih.gov/34393988/.
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: pubmed.ncbi.nlm.nih.gov/34129181/.
Atypical thrombosis associated with the vaccine VaxZevria (AstraZeneca): data from the French network of regional pharmacovigilance centers: pubmed.ncbi.nlm.nih.gov/34083026/.
Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34247246/.
Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: pubmed.ncbi.nlm.nih.gov/34375510/
Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34355379/.
Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34416410/.
Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34224024/.
Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: pubmed.ncbi.nlm.nih.gov/34043800/.
Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: pubmed.ncbi.nlm.nih.gov/34447646/
Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: pubmed.ncbi.nlm.nih.gov/34479760/.
fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: pubmed.ncbi.nlm.nih.gov/34416319/.
Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): pubmed.ncbi.nlm.nih.gov/34092166/
Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34291477/
Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34513435/
Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: pubmed.ncbi.nlm.nih.gov/34483273/.
Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: pubmed.ncbi.nlm.nih.gov/34513446/
Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: pubmed.ncbi.nlm.nih.gov/34474550/
Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: pubmed.ncbi.nlm.nih.gov/33858208/
Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: pubmed.ncbi.nlm.nih.gov/34015240/
Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): pubmed.ncbi.nlm.nih.gov/34469919/.
Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: pubmed.ncbi.nlm.nih.gov/34516272/.
Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: pubmed.ncbi.nlm.nih.gov/34512961/
Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: pubmed.ncbi.nlm.nih.gov/34350668/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/.
COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: pubmed.ncbi.nlm.nih.gov/34509271/.
Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34462996/
COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: pubmed.ncbi.nlm.nih.gov/34435142/
Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34236711/
Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: pubmed.ncbi.nlm.nih.gov/33857630/.
The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34455073/
Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: pubmed.ncbi.nlm.nih.gov/34116145/
Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: pubmed.ncbi.nlm.nih.gov/34286453/.
Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: pubmed.ncbi.nlm.nih.gov/34478433/
Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: pubmed.ncbi.nlm.nih.gov/34244448/
Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34226070/
Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: pubmed.ncbi.nlm.nih.gov/34393988/.
Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: pubmed.ncbi.nlm.nih.gov/34407607/.
Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: pubmed.ncbi.nlm.nih.gov/34313952/
Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): pubmed.ncbi.nlm.nih.gov/34092166/
Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: pubmed.ncbi.nlm.nih.gov/34293217/
A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: pubmed.ncbi.nlm.nih.gov/34274191/
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: pubmed.ncbi.nlm.nih.gov/34186376/
Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: pubmed.ncbi.nlm.nih.gov/33952445/
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: pubmed.ncbi.nlm.nih.gov/34129181/
U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination...
#6 U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: pubmed.ncbi.nlm.nih.gov/33929487/.
Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34341358/
Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/
Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/.
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/
Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34373991/
Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34490632/
An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33909350/
Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: pubmed.ncbi.nlm.nih.gov/33981305/.
A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. pubmed.ncbi.nlm.nih.gov/34272622/
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. pubmed.ncbi.nlm.nih.gov/33877737/
Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34254476/
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: pubmed.ncbi.nlm.nih.gov/34108714/
ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: pubmed.ncbi.nlm.nih.gov/34483267/.
Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261635/
Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: pubmed.ncbi.nlm.nih.gov/34202817/
A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34276917/
Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34237213/.
Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34268278/.
Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/33990339/.
Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: pubmed.ncbi.nlm.nih.gov/34479760/.
Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: pubmed.ncbi.nlm.nih.gov/34314875/.
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: pubmed.ncbi.nlm.nih.gov/34382387/
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/.
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/
Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: t.co/j0IEM8cMXI
A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: pubmed.ncbi.nlm.nih.gov/34601006/
This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: www.nejm.org/doi/full/10.1056/NEJMoa2110475
Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: pubmed.ncbi.nlm.nih.gov/34626338/
A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: europepmc.org/article/PPR/PPR304469 435.
Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/
Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34461442/
Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34373413/
Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34598301/
Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca...
Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: pubmed.ncbi.nlm.nih.gov/34696248/
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: pubmed.ncbi.nlm.nih.gov/34545400/
Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34035134/
In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34688190/
Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: pubmed.ncbi.nlm.nih.gov/34782400/
Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34710832/
Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: pubmed.ncbi.nlm.nih.gov/34644642/
Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34726934/
Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: pubmed.ncbi.nlm.nih.gov/34835237/
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/
Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34724036/.
COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: pubmed.ncbi.nlm.nih.gov/34624910/
Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34580132/.
A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: pubmed.ncbi.nlm.nih.gov/34535492/
Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: pubmed.ncbi.nlm.nih.gov/34272095/
Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: pubmed.ncbi.nlm.nih.gov/34756770/
Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: pubmed.ncbi.nlm.nih.gov/34706921/
COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: pubmed.ncbi.nlm.nih.gov/34698582/.
Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: pubmed.ncbi.nlm.nih.gov/34327553/.
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33877737/
Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34646685/
Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34242687/.
Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): pubmed.ncbi.nlm.nih.gov/34006408/
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/
Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: pubmed.ncbi.nlm.nih.gov/34664303/.
Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34649281/.
Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: pubmed.ncbi.nlm.nih.gov/34420249/
Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: pubmed.ncbi.nlm.nih.gov/34610990/.
Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: pubmed.ncbi.nlm.nih.gov/34819146/.
Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: pubmed.ncbi.nlm.nih.gov/34755433/
Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: pubmed.ncbi.nlm.nih.gov/34667486/
Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: pubmed.ncbi.nlm.nih.gov/34726187/.
Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: pubmed.ncbi.nlm.nih.gov/34595694/
Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: pubmed.ncbi.nlm.nih.gov/34661934/
Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34788138
A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: pubmed.ncbi.nlm.nih.gov/34769454/
Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: pubmed.ncbi.nlm.nih.gov/34833382/
Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): pubmed.ncbi.nlm.nih.gov/34670287/
Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: pubmed.ncbi.nlm.nih.gov/34023956/.
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/
Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34842783/
Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34630307/
Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: pubmed.ncbi.nlm.nih.gov/34579248/
A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: pubmed.ncbi.nlm.nih.gov/34843991/
Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34407607/
Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: pubmed.ncbi.nlm.nih.gov/34639132/
Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: pubmed.ncbi.nlm.nih.gov/34804412/
Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/
Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/
*
Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34435250/
COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: pubmed.ncbi.nlm.nih.gov/34186348/.
GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: www.sciencedirect.com/science/article/pii/S2666354621000065
Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: www.sciencedirect.com/science/article/pii/S0303846721004169
Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: www.sciencedirect.com/science/article/pii/S0165572821002186
Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: www.sciencedirect.com/science/article/pii/S2214250921000998.
Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: www.sciencedirect.com/science/article/pii/S0736467921006442
Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: www.sciencedirect.com/science/article/pii/S0035378721005853.
SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: www.sciencedirect.com/science/article/pii/S2049080121005343
Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: www.sciencedirect.com/science/article/pii/S2049080121007536
Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: www.sciencedirect.com/science/article/pii/S1201971221007049
Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: www.sciencedirect.com/science/article/pii/S0899707121003557.
New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: www.sciencedirect.com/science/article/pii/S0165572821001569
Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: www.sciencedirect.com/science/article/pii/S0165572821002137
Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story: www.sciencedirect.com/science/article/pii/S1473309921002735
Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: www.sciencedirect.com/science/article/pii/S266635462100020X
Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:. www.sciencedirect.com/science/article/pii/S2451993621001456.
Bell’s palsy after COVID-19 vaccination: case report: www.sciencedirect.com/science/article/pii/S217358082100122X.
An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history: www.sciencedirect.com/science/article/pii/S2213219821007972
COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: www.sciencedirect.com/science/article/pii/S1930043321002612
ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: www.sciencedirect.com/science/article/pii/S0272638621007423
Late cutaneous reactions after administration of COVID-19 mRNA vaccines: www.sciencedirect.com/science/article/pii/S2213219821007996
COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: www.sciencedirect.com/science/article/pii/S1871402121001880
Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: www.sciencedirect.com/science/article/pii/S0190962221024427
Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. www.sciencedirect.com/science/article/abs/pii/S0735675721004381.
COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:. www.sciencedirect.com/science/article/pii/S1939455121000119.
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. www.sciencedirect.com/science/article/pii/S1871402121002046.
Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. www.sciencedirect.com/science/article/abs/pii/S188558572100133X
Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:. www.sciencedirect.com/science/article/pii/S0896841121000937.
immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:. www.sciencedirect.com/science/article/pii/S2214250921002018.
Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: www.sciencedirect.com/science/article/pii/S1876034121001878.
COVID-19 RNA-based vaccines and the risk of prion disease: scivisionpub.com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion- ease-1503.pdf
This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: www.nejm.org/doi/full/10.1056/NEJMoa2104983.
Process-related impurities in the ChAdOx1 nCov-19 vaccine: www.researchsquare.com/article/rs-477964/v1
COVID-19 mRNA vaccine causing CNS inflammation: a case series: link.springer.com/article/10.1007/s00415-021-10780-7
Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33475702/
Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: pubmed.ncbi.nlm.nih.gov/33320974/
Pfizer Vaccine Raises Allergy Concerns: pubmed.ncbi.nlm.nih.gov/33384356/
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: pubmed.ncbi.nlm.nih.gov/33444297/
Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: pubmed.ncbi.nlm.nih.gov/33507892/
Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: pubmed.ncbi.nlm.nih.gov/34414880/
Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: pubmed.ncbi.nlm.nih.gov/33576785/
Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: pubmed.ncbi.nlm.nih.gov/34269740/
Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34215453/
Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: pubmed.ncbi.nlm.nih.gov/33932618/
Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): pubmed.ncbi.nlm.nih.gov/33643776/
Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/33571463/
Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: pubmed.ncbi.nlm.nih.gov/33527524/
Cutaneous adverse effects of available COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34518015/
Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: pubmed.ncbi.nlm.nih.gov/34347278/
COVID-19 vaccines increase the risk of anaphylaxis: pubmed.ncbi.nlm.nih.gov/33685103/
Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/
Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: pubmed.ncbi.nlm.nih.gov/33657648/
Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33825239/
Acute allergic reactions to COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/33683290/
Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: pubmed.ncbi.nlm.nih.gov/33919151/
Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: pubmed.ncbi.nlm.nih.gov/34128049/
Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: pubmed.ncbi.nlm.nih.gov/34474708/
Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447
.IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34318537/
Allergic reactions after COVID-19 vaccination: putting the risk in perspective...
*
Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: pubmed.ncbi.nlm.nih.gov/33846043/ 188.
Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: pubmed.ncbi.nlm.nih.gov/33752263/
COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: pubmed.ncbi.nlm.nih.gov/34073536/
Fatal brain hemorrhage after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33928772/
A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: pubmed.ncbi.nlm.nih.gov/34423106/
Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: pubmed.ncbi.nlm.nih.gov/33838206/
Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: pubmed.ncbi.nlm.nih.gov/34517079/
Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: pubmed.ncbi.nlm.nih.gov/34254291/
Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: pubmed.ncbi.nlm.nih.gov/34487581/
Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: pubmed.ncbi.nlm.nih.gov/33987882/
Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34138513/
Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: pubmed.ncbi.nlm.nih.gov/34402235/
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: pubmed.ncbi.nlm.nih.gov/34446426/
Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: pubmed.ncbi.nlm.nih.gov/34365148/.
Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: pubmed.ncbi.nlm.nih.gov/34452064/.
A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33917902/
Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): pubmed.ncbi.nlm.nih.gov/34256983/
Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34247246/.
Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34132839/
59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34117206/
Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: pubmed.ncbi.nlm.nih.gov/34033927/
Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34277198/
Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: pubmed.ncbi.nlm.nih.gov/34364831/
Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: pubmed.ncbi.nlm.nih.gov/34447639/
Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: pubmed.ncbi.nlm.nih.gov/34514306/
Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/
Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: pubmed.ncbi.nlm.nih.gov/34453510/
Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: pubmed.ncbi.nlm.nih.gov/33476455/
propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34451967/
Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34377889/
Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: pubmed.ncbi.nlm.nih.gov/34272095/
COVID-19 vaccination association and facial nerve palsy: A case-control study: pubmed.ncbi.nlm.nih.gov/34165512/
The association between COVID-19 vaccination and Bell’s palsy: pubmed.ncbi.nlm.nih.gov/34411533/
Bell’s palsy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33611630/
Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): pubmed.ncbi.nlm.nih.gov/33981305/
Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: pubmed.ncbi.nlm.nih.gov/34336436/
Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34281950/.
Transverse myelitis induced by SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34458035/
Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): pubmed.ncbi.nlm.nih.gov/33734623/
Acute abducens nerve palsy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34044114/.
Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: pubmed.ncbi.nlm.nih.gov/34492394/
Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34369471/
Bell’s palsy after Ad26.COV2.S COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34014316/
Bell’s palsy after COVID-19 vaccination: case report: pubmed.ncbi.nlm.nih.gov/34330676/
A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34272622/
Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19: pubmed.ncbi.nlm.nih.gov/34477091/
Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/33975372/.
Bell’s palsy after COVID-19 vaccination with high antibody response in CSF: pubmed.ncbi.nlm.nih.gov/34322761/.
Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: pubmed.ncbi.nlm.nih.gov/34139321/.
Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: pubmed.ncbi.nlm.nih.gov/34032902/.
Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?: pubmed.ncbi.nlm.nih.gov/33862041/
Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34332438/
Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: pubmed.ncbi.nlm.nih.gov/34293683/.
Autoimmune hepatitis after COVID vaccine: pubmed.ncbi.nlm.nih.gov/34225251/
A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: pubmed.ncbi.nlm.nih.gov/34449715/
Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: pubmed.ncbi.nlm.nih.gov/34139631/.
Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/33864750/
Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/33914590/
Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34420802/
Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: pubmed.ncbi.nlm.nih.gov/34293217/
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: pubmed.ncbi.nlm.nih.gov/34446426/
Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34174723/
Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: pubmed.ncbi.nlm.nih.gov/33952445/
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: pubmed.ncbi.nlm.nih.gov/34108714/
Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: pubmed.ncbi.nlm.nih.gov/34288044/
Malignant cerebral infarction after...
*
celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: pubmed.ncbi.nlm.nih.gov/34261633/.
Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34256983/
Thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34332437/.
Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33845870/.
Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: pubmed.ncbi.nlm.nih.gov/34236343/
Acute myocardial infarction within 24 hours after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34364657/.
Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34287612/
central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: pubmed.ncbi.nlm.nih.gov/34478433/
Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: pubmed.ncbi.nlm.nih.gov/34402235/
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: pubmed.ncbi.nlm.nih.gov/34186376/
Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34101024/
A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34137813/
Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: pubmed.ncbi.nlm.nih.gov/34191218/
Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/
New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34153802/
Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: pubmed.ncbi.nlm.nih.gov/34092488/
Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261635/
Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34132839/.
Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34144250/
Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/33687691/
Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34011137/.
Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: pubmed.ncbi.nlm.nih.gov/34393988/.
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: pubmed.ncbi.nlm.nih.gov/34129181/.
Atypical thrombosis associated with the vaccine VaxZevria
Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34247246/.
Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: pubmed.ncbi.nlm.nih.gov/34235757/.
Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34473841/.
Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34189756/
Cerebral venous thrombosis following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34045111/.
Lipschütz ulcers after AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34366434/.
Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: pubmed.ncbi.nlm.nih.gov/34330677/
Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: pubmed.ncbi.nlm.nih.gov/34181446/
Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34477089/
Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: pubmed.ncbi.nlm.nih.gov/34071883/
Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34033367/
Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: pubmed.ncbi.nlm.nih.gov/34375510/
Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34107198/
Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34355379/.
A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: pubmed.ncbi.nlm.nih.gov/34452028/
Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: pubmed.ncbi.nlm.nih.gov/34202817/
Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34237213/.
Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: pubmed.ncbi.nlm.nih.gov/34105247/.
Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34405870/.
Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34416410/.
Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: pubmed.ncbi.nlm.nih.gov/34462013/.
Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34224024/.
Post-vaccinal encephalitis after ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34324214/
Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: pubmed.ncbi.nlm.nih.gov/34507266/
Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: pubmed.ncbi.nlm.nih.gov/34459725/
Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: pubmed.ncbi.nlm.nih.gov/34463066/
Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: pubmed.ncbi.nlm.nih.gov/34043800/.
Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: pubmed.ncbi.nlm.nih.gov/34447646/
Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: pubmed.ncbi.nlm.nih.gov/34479760/.
fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: pubmed.ncbi.nlm.nih.gov/34416319/.
Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): pubmed.ncbi.nlm.nih.gov/34092166/
Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34291477/
Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34513435/
Hepatitis C virus reactivation after COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34512037/
Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: pubmed.ncbi.nlm.nih.gov/34483273/.
Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: pubmed.ncbi.nlm.nih.gov/34513446/
Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: pubmed.ncbi.nlm.nih.gov/34474550/
Reactive arthritis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34033732/.
Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: pubmed.ncbi.nlm.nih.gov/33858208/
Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: pubmed.ncbi.nlm.nih.gov/34015240/
Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34482558/
COVID-19 mRNA vaccine causing CNS inflammation: a case series: pubmed.ncbi.nlm.nih.gov/34480607/
Thymic
*
Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34325334/
Tolosa-Hunt syndrome occurring after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34513398/
Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): pubmed.ncbi.nlm.nih.gov/34469919/.
Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: pubmed.ncbi.nlm.nih.gov/34516272/.
Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: pubmed.ncbi.nlm.nih.gov/34512961/
Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34077949/
Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34171435/
Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34447349/
Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34514078/
Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34406660/.
IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34509658/
A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34196469/.
Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: pubmed.ncbi.nlm.nih.gov/34350668/
Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34436620/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/.
COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: pubmed.ncbi.nlm.nih.gov/34509271/.
Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34462996/
Immune thrombocytopenia after vaccination during the COVID-19 pandemic: pubmed.ncbi.nlm.nih.gov/34435486/
COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: pubmed.ncbi.nlm.nih.gov/34435142/
Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34429981/
Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: pubmed.ncbi.nlm.nih.gov/34427024/
Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34510014/.
Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34236711/
Vaccine-induced thrombocytopenia with severe headache: pubmed.ncbi.nlm.nih.gov/34525282/
Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34515024/
Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34435250/.
Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34363637/
Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: www.sciencedirect.com/science/article/pii/S2214250921002018
Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: casereports.bmj.com/content/14/5/e242220.abstract.
Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34155844/
Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/.
Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext.
Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/.
Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: casereports.bmj.com/content/14/7/e242678.
Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-
Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794
COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines
Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: pubmed.ncbi.nlm.nih.gov/34288044/.
Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: pubmed.ncbi.nlm.nih.gov/34327553/.
Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33878469/.
Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: pubmed.ncbi.nlm.nih.gov/33857630/.
Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34090750/.
Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34312301/.
Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34333995/
The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34455073/
Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34111775/.
Cerebral venous thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34045111/
Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33983464/
Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: pubmed.ncbi.nlm.nih.gov/34116145/
Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: pubmed.ncbi.nlm.nih.gov/34286453/.
Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: pubmed.ncbi.nlm.nih.gov/34478433/
Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: pubmed.ncbi.nlm.nih.gov/34244448/
Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34226070/
Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: pubmed.ncbi.nlm.nih.gov/33845870/.
Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34101024/.
Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: pubmed.ncbi.nlm.nih.gov/34393988/.
Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: pubmed.ncbi.nlm.nih.gov/34407607/.
Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: pubmed.ncbi.nlm.nih.gov/34313952/
Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): pubmed.ncbi.nlm.nih.gov/34092166/
Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: pubmed.ncbi.nlm.nih.gov/34293217/
A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: pubmed.ncbi.nlm.nih.gov/34274191/
Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: pubmed.ncbi.nlm.nih.gov/34186376/
Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: pubmed.ncbi.nlm.nih.gov/33952445/
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: pubmed.ncbi.nlm.nih.gov/34129181/
U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination...
*
Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34341358/
Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/
Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/.
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/
Autoimmunity roots of thrombotic events after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34508917/
Cerebral venous sinus thrombosis after vaccination: the UK experience: pubmed.ncbi.nlm.nih.gov/34370974/
Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34373991/
Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34490632/
An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33909350/
Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: pubmed.ncbi.nlm.nih.gov/33981305/.
A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. pubmed.ncbi.nlm.nih.gov/34272622/
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. pubmed.ncbi.nlm.nih.gov/33877737/
Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34254476/
First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: pubmed.ncbi.nlm.nih.gov/34108714/
ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: pubmed.ncbi.nlm.nih.gov/34483267/.
Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261635/
Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: pubmed.ncbi.nlm.nih.gov/34202817/
Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: pubmed.ncbi.nlm.nih.gov/34273119/
Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: pubmed.ncbi.nlm.nih.gov/34463066/
A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34276917/
Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34237213/.
Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34268278/.
Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/33990339/.
Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: pubmed.ncbi.nlm.nih.gov/34479760/.
Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: pubmed.ncbi.nlm.nih.gov/34314875/.
Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34384129/
Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: pubmed.ncbi.nlm.nih.gov/34382387/
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/.
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/
Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34261296/
Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: pubmed.ncbi.nlm.nih.gov/34250318/.
A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: pubmed.ncbi.nlm.nih.gov/34059191/
Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34189756/
Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34331506/
Vaccine-induced thrombocytopenia with severe headache: pubmed.ncbi.nlm.nih.gov/34525282/
Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: www.medrxiv.org/content/10.1101/2021.08.30.21262866v1
COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09.
Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: onlinelibrary.wiley.com/doi/10.1111/trf.16672
Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: t.co/j0IEM8cMXI
A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: pubmed.ncbi.nlm.nih.gov/34601006/
This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: www.nejm.org/doi/full/10.1056/NEJMoa2110475
Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: www.sciencedirect.com/science/article/pii/S1201971221007797
Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: www.medrxiv.org/content/10.1101/2021.08.30.21262866v1.
Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: www.sciencedirect.com/science/article/pii/S0168827821020936
Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: www.nature.com/articles/s41421-021-00329-3
Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/
Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:www.science.org/doi/10.1126/sciadv.abl8213
Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: pubmed.ncbi.nlm.nih.gov/34626338/
A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: europepmc.org/article/PPR/PPR304469 435.
VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34731555/
Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/
Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34461442/
Spectrum of neurological complications after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34719776/.
Cerebral venous sinus thrombosis after vaccination: the UK experience: pubmed.ncbi.nlm.nih.gov/34370974/
Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34373413/
Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34598301/
Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca...
*
Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: pubmed.ncbi.nlm.nih.gov/34650896/
Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34625447/
Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: pubmed.ncbi.nlm.nih.gov/34696248/
Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34548920/
Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): pubmed.ncbi.nlm.nih.gov/34672380/.
Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: pubmed.ncbi.nlm.nih.gov/34556531/.
Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: pubmed.ncbi.nlm.nih.gov/34535076/.
Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: pubmed.ncbi.nlm.nih.gov/34379914/.
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: pubmed.ncbi.nlm.nih.gov/34545400/
Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34035134/
In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34688190/
Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: pubmed.ncbi.nlm.nih.gov/34782400/
Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34710832/
Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: pubmed.ncbi.nlm.nih.gov/34695859/
Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: pubmed.ncbi.nlm.nih.gov/34453762/.
Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: pubmed.ncbi.nlm.nih.gov/34660652/.
Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: pubmed.ncbi.nlm.nih.gov/34644642/
Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: pubmed.ncbi.nlm.nih.gov/34694650/
Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34726934/
Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: pubmed.ncbi.nlm.nih.gov/34835237/
Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/
Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34724036/.
Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34839563/
Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34783932/.
COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: pubmed.ncbi.nlm.nih.gov/34624910/
Inflammatory myositis after vaccination with ChAdOx1: pubmed.ncbi.nlm.nih.gov/34585145/
Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34580132/.
A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: pubmed.ncbi.nlm.nih.gov/34535492/
COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: pubmed.ncbi.nlm.nih.gov/34527501/
Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: pubmed.ncbi.nlm.nih.gov/34272095/
Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: pubmed.ncbi.nlm.nih.gov/34756770/
Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: jamanetwork.com/journals/jamaneurology/fullarticle/2784622
Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34781321/
Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: pubmed.ncbi.nlm.nih.gov/34062319/
Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: pubmed.ncbi.nlm.nih.gov/34706921/
COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: pubmed.ncbi.nlm.nih.gov/34698582/.
Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34751013/.
Acute transverse myelitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34684047/.
Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34541935/
Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34273119/
Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: pubmed.ncbi.nlm.nih.gov/34327553/.
Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33877737/
Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34646685/
Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34242687/.
Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34609603/
Case report: Pityriasis rosea-like rash after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34557507/
Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34641797/.
Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: pubmed.ncbi.nlm.nih.gov/34812326/.
Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): pubmed.ncbi.nlm.nih.gov/34006408/
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/
Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: pubmed.ncbi.nlm.nih.gov/34664303/.
Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34649281/.
Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: pubmed.ncbi.nlm.nih.gov/34420249/
Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: pubmed.ncbi.nlm.nih.gov/34610990/.
Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: pubmed.ncbi.nlm.nih.gov/34590397/
Sudden sensorineural hearing loss after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34670143/.
Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: pubmed.ncbi.nlm.nih.gov/34819146/.
Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: pubmed.ncbi.nlm.nih.gov/34581453/
Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: pubmed.ncbi.nlm.nih.gov/34741583/
Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34631069/
Thrombosis after COVID-19 vaccination: possible link to ACE pathways: pubmed.ncbi.nlm.nih.gov/34479129/
Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34331506/
Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): pubmed.ncbi.nlm.nih.gov/34546608/
Abdominal pain and bilateral...
*
Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34849183/
Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34853744/.
A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): pubmed.ncbi.nlm.nih.gov/34751429/.
Ocular adverse events following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34559576/
Depression after ChAdOx1-S / nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34608345/.
Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34384129/.
Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: pubmed.ncbi.nlm.nih.gov/34755433/
Major artery thrombosis and vaccination against ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34839830/
Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: pubmed.ncbi.nlm.nih.gov/34667486/
Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: pubmed.ncbi.nlm.nih.gov/34726187/.
Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34781027/
Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: pubmed.ncbi.nlm.nih.gov/34595694/
Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: pubmed.ncbi.nlm.nih.gov/34661934/
Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34788138
Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34753210/.
Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34653943/.
Relapse of immune thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34591991/
Thrombosis in pre- and post-vaccination phase of COVID-19; pubmed.ncbi.nlm.nih.gov/34650382/
A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: pubmed.ncbi.nlm.nih.gov/34769454/
COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: pubmed.ncbi.nlm.nih.gov/34786893/
Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: pubmed.ncbi.nlm.nih.gov/34833382/
Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): pubmed.ncbi.nlm.nih.gov/34670287/
An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34790811/
Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: pubmed.ncbi.nlm.nih.gov/34023956/.
Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: pubmed.ncbi.nlm.nih.gov/34629931/
Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/
Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34842783/
Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34630307/
Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33983464/
Autoimmune roots of thrombotic events after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34508917/.
New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.
Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca
Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: pubmed.ncbi.nlm.nih.gov/34796065/.
Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: pubmed.ncbi.nlm.nih.gov/34579248/
A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: pubmed.ncbi.nlm.nih.gov/34843991/
Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): pubmed.ncbi.nlm.nih.gov/34595867/
A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): pubmed.ncbi.nlm.nih.gov/34820240/
Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors: pubmed.ncbi.nlm.nih.gov/33851389/
Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: pubmed.ncbi.nlm.nih.gov/33980419/
Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34264151/
Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: pubmed.ncbi.nlm.nih.gov/34734086/
Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: pubmed.ncbi.nlm.nih.gov/34755555/
Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34407607/
Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: pubmed.ncbi.nlm.nih.gov/34264514/.
Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): pubmed.ncbi.nlm.nih.gov/34840204/
Neurological side effects of SARS-CoV-2 vaccines: pubmed.ncbi.nlm.nih.gov/34750810/
Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: pubmed.ncbi.nlm.nih.gov/34639132/
Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: pubmed.ncbi.nlm.nih.gov/34804412/
Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: pubmed.ncbi.nlm.nih.gov/34571653/.
Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: pubmed.ncbi.nlm.nih.gov/34835275/.
Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: pubmed.ncbi.nlm.nih.gov/34659839/.
Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34668274/.
Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34549821/
Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): pubmed.ncbi.nlm.nih.gov/34528522/
Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/
Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/.
Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408
Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: www.mdpi.com/2075-4426/11/11/1106
Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/
Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/
Myocarditis Following mRNA COVID-19 Vaccine: journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.
Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: pubmed.ncbi.nlm.nih.gov/34614328/.
Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext
Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34277198/
Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: pubmed.ncbi.nlm.nih.gov/34246586/
Hypersensitivity Myocarditis and...